+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

France Inflammatory Bowel Disease (IBD) Market 2019-2025

  • ID: 5124899
  • Report
  • March 2020
  • Region: France
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • 1. AbbVie Inc.
  • 10. UCB, Inc.
  • 11. Vifor Pharma Group
  • 2. Allergan, PLC
  • 4. Eli Lilly and Co.
  • 6. Pfizer Inc.
France Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), by Treatment Type (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025.

France IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.6% during the forecast period. The growing IBD patient population is one of the major driving forces for the growth of the market in the country. According to the National Institutes of, Health, the total number of cases associated with Crohn's disease in France were registered to be around 72,522 in 2017. This signifies the opportunity for the increase in demand for treatment alternatives for Crohn's disease in the country. Moreover, the prevalence of smoking in France is also high. Although the prevalence rate of smoking is decreasing in the country still the current rate is on a higher side. This is expected to increase the risk associated with the prevalence of IBD in the country. Owing to this as the prevalence of the IBD increases, it is expected to supplement the demand for treatment options for IBD thereby promoting the growth of the market.

France IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. For Crohn's and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

The companies which are contributing to the growth of the France IBD therapeutics market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., Pharmacosmos A/S, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of France IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

Market Segmentation:

1. France IBD Market Research and Analysis by Disease Type
2. France IBD Market Research and Analysis by Treatment type

The Report covers:
  • Comprehensive research methodology of the France IBD therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the France IBD therapeutics market.
  • Insights about market determinants which are stimulating the France IBD therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1. AbbVie Inc.
  • 10. UCB, Inc.
  • 11. Vifor Pharma Group
  • 2. Allergan, PLC
  • 4. Eli Lilly and Co.
  • 6. Pfizer Inc.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. France IBD Therapeutics Market by Disease Type
5.1.1. Ulcerative Colitis
5.1.2. Crohn’s Disease
5.2. France IBD Therapeutics Market by Treatment Type
5.2.1. Surgery
5.2.2. Anti- Inflammatory Drug Administration
5.2.2.1. Steroids
5.2.2.2. Immunosuppressant
5.2.2.3. Biological Drugs
5.2.2.4. Amino salicylates
5.2.2.5. Others

6. Company Profiles
6.1. AbbVie Inc.
6.2. Allergan, PLC
6.3. Boehringer Ingelheim International GmbH
6.4. Eli Lilly and Co.
6.5. Johnson & Johnson Services Inc.
6.6. Pfizer Inc.
6.7. Pharmacosmos A/S
6.8. Sanofi S.A.
6.9. Takeda pharmaceutical Co., Ltd.
6.10. UCB, Inc.
6.11. Vifor Pharma Group

LIST OF TABLES
1. FRANCE IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
2. FRANCE IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES
1. FRANCE IBD THERAPEUTICS MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
2. FRANCE IBD THERAPEUTICS MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 1. AbbVie Inc.
  • 2. Allergan, PLC
  • 3. Boehringer Ingelheim International GmbH
  • 4. Eli Lilly and Co.
  • 5. Johnson & Johnson Services Inc.
  • 6. Pfizer Inc.
  • 7. Pharmacosmos A/S
  • 8. Sanofi S.A.
  • 9. Takeda pharmaceutical Co., Ltd.
  • 10. UCB, Inc.
  • 11. Vifor Pharma Group
Note: Product cover images may vary from those shown